- Home
- DTSQ vs RVPH Comparison
DTSQ vs RVPH Comparison
Compare DTSQ & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSQ
- RVPH
- Stock Information
- Founded
- DTSQ 2022
- RVPH 2006
- Country
- DTSQ United States
- RVPH United States
- Employees
- DTSQ N/A
- RVPH N/A
- Industry
- DTSQ
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- DTSQ
- RVPH Health Care
- Exchange
- DTSQ NYSE
- RVPH Nasdaq
- Market Cap
- DTSQ 89.8M
- RVPH 88.0M
- IPO Year
- DTSQ 2024
- RVPH N/A
- Fundamental
- Price
- DTSQ $10.16
- RVPH $1.87
- Analyst Decision
- DTSQ
- RVPH Strong Buy
- Analyst Count
- DTSQ 0
- RVPH 5
- Target Price
- DTSQ N/A
- RVPH $11.40
- AVG Volume (30 Days)
- DTSQ 31.8K
- RVPH 1.5M
- Earning Date
- DTSQ 01-01-0001
- RVPH 11-14-2024
- Dividend Yield
- DTSQ N/A
- RVPH N/A
- EPS Growth
- DTSQ N/A
- RVPH N/A
- EPS
- DTSQ 0.17
- RVPH N/A
- Revenue
- DTSQ N/A
- RVPH N/A
- Revenue This Year
- DTSQ N/A
- RVPH N/A
- Revenue Next Year
- DTSQ N/A
- RVPH N/A
- P/E Ratio
- DTSQ $61.02
- RVPH N/A
- Revenue Growth
- DTSQ N/A
- RVPH N/A
- 52 Week Low
- DTSQ $9.96
- RVPH $0.60
- 52 Week High
- DTSQ $10.16
- RVPH $4.72
- Technical
- Relative Strength Index (RSI)
- DTSQ N/A
- RVPH 48.62
- Support Level
- DTSQ N/A
- RVPH $1.97
- Resistance Level
- DTSQ N/A
- RVPH $2.14
- Average True Range (ATR)
- DTSQ 0.00
- RVPH 0.16
- MACD
- DTSQ 0.00
- RVPH -0.01
- Stochastic Oscillator
- DTSQ 0.00
- RVPH 40.43
About DTSQ DT CLOUD STAR ACQUISITION CORP
DT Cloud Star Acquisition Corp is a blank check company.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.